Trevi Therapeutics, Inc. (TRVI)
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization Haduvio to treat serious neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson’s disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good in March 2011 and is headquartered in New Haven, CT.
Address
195 CHURCH STREET
NEW HAVEN, CT 06510
Founded
2011
Number of Employees
25
Website
http://www.trevitherapeutics.com
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)